←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Regulation, FDA Oncology
Harpreet Singh
MD
🏢US Food and Drug Administration🌐USA
Director, Division of Oncology 2
35
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Harpreet Singh directs oncology drug review at FDA and has contributed to the approval of multiple therapies for genitourinary and rare cancers. Her work has emphasized access for patients with rare malignancies and pediatric cancers. She contributes to FDA oncology policy and guidance development.
Share:
🧪Research Fields 研究领域
oncology regulation
rare cancers
renal cell carcinoma
FDA review
drug approval
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Harpreet Singh 的研究动态
Follow Harpreet Singh's research updates
留下邮箱，当我们发布与 Harpreet Singh（US Food and Drug Administration）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment